Must reads

• A November 6, 2014 Reuters article reported on efforts of drugmakers to "push the boundaries of old age." According to the article, "Google's ambition to defy the limits of ageing has fired up interest in the field, drawing in drug companies who are already quietly pioneering research, despite the regulatory and clinical hurdles that remain…By 2020 people aged 60 and older will outnumber children younger than five for the first time in history, according to a paper published in the Lancet medical journal on Thursday…The goal is not to create some "elixir of life" pill to help people live ever longer, but rather to maximise healthy lifespan and reduce the period of end-of-life sickness and dependency."
• A November 6, 2014 Eureka Alert post announced that one researcher believes that "failed Alzheimer's test shows in which direction the research should continue." According to the post, "In the prestigious journal Cell, the Alzheimer's expert Bart De Strooper...argues that these studies are not pointless, but merely indicate what the next steps should be for the Alzheimer's research. This article - or rather, this message - will be spread at the largest Neuroscience meeting that will take place mid-November in Washington."
• A November 5, 2015 Washington University in St. Louis news post announced that "The National Institutes of Health (NIH) has boosted funding for the first large-scale clinical trial aimed at identifying drugs to stop or slow Alzheimer’s disease in people destined to get the debilitating illness." According to the article, "The National Institute on Aging of the NIH has awarded $5.5 million in funding to continue and expand the trial, which is focused on dominantly inherited forms of Alzheimer’s disease. In all, the National Institute on Aging will provide an estimated total of $26 million in funding over the next five years to support the groundbreaking trial."